The Food and Drug Administration (FDA) has accepted for review a resubmission of the Biologics License Application (BLA) for bevacizumab-vikg (ONS-5010) for the treatment of wet age-related macular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback